Poxel Announces Participation at Upcoming Scientific and Investor Conferences
21 Septembre 2020 - 05:45PM
Business Wire
POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical
company focused on the development of innovative treatments for
metabolic disorders, including type 2 diabetes and non-alcoholic
steatohepatitis (NASH), today announced that members of the Poxel
management and scientific team will participate at upcoming
scientific and investor conferences.
56th European Association for the Study of Diabetes (EASD)
Annual Meeting Date: September 21-25, 2020 (virtual conference)
Members of Poxel’s scientific team will present posters on
Imeglimin Phase 3 TIMES 2 and TIMES 3 results. In addition, a
poster will be presented on PXL770 preclinical cardio-renal
results. Details on the poster sessions are included below:
TIMES 2: Title: Long-term treatment with imeglimin as
add-on to oral antidiabetes therapy in Japanese patients with type
2 diabetes, results of TIMES 2, a Phase 3 trial Session: PS 52 Novel glucose-lowering agents in
type 2 diabetes Date: September 23,
2020; 1:15 - 2:15 pm CEST
TIMES 3: Title: Efficacy and safety of imeglimin in
combination with insulin in Japanese patients with type 2 diabetes:
results of TIMES 3, a Phase 3 trial Session: PS 52 Novel glucose-lowering agents in
type 2 diabetes Date: September 23,
2020; 1:15 - 2:15 pm CEST
PXL770: Title: Chronic treatment with the direct AMP
kinase activator PXL770 improves cardiac and renal function in
diabetes related cardiorenal syndrome Session: PS 88 Cardiac complications: of mice,
rats and cells Date: September 23,
2020; 1:15 to 2:15 pm CEST
4th Annual H.C. Wainwright Virtual NASH Investor Conference
Date: October 5, 2020 Members of the Poxel management team will
present an overview of Poxel’s two NASH clinical-stage candidates,
PXL770 and PXL065. PXL770 is a first-in-class, oral direct
adenosine monophosphate-activated protein kinase (AMPK) activator.
PXL065 is a novel, oral, proprietary deuterium-stabilized
R-stereoisomer of pioglitazone.
HealthTech Innovation Days (France Biotech) Conference
Date: October 5-6, 2020 Members of the Poxel management team
will be available for one-on-one virtual meetings.
About Poxel SA
Poxel is a dynamic biopharmaceutical company that uses
its extensive expertise in developing innovative drugs for
metabolic diseases, with a focus on type 2 diabetes and
non-alcoholic steatohepatitis (NASH). In its mid-to-late
stage pipeline, the Company is currently advancing three drug
candidates as well as earlier-stage opportunities.
Imeglimin, Poxel’s first-in-class lead product, targets
mitochondrial dysfunction. Together, with its partner Sumitomo
Dainippon Pharma, Poxel successfully completed the Phase 3
Trials of IMeglimin for Efficacy and
Safety (TIMES) program for the treatment of type 2 diabetes
in Japan. Poxel also established a partnership with Roivant
Sciences for Imeglimin’s development and commercialization in
countries outside of the partnership with Sumitomo Dainippon
Pharma, including the U.S. and Europe. PXL770, a
first-in-class direct adenosine monophosphate-activated protein
kinase (AMPK) activator, is in a Phase 2a proof-of-concept program
for the treatment of NASH. PXL770 could also have the potential to
treat additional metabolic diseases. PXL065
(deuterium-stabilized R-pioglitazone), a mitochondrial pyruvate
carrier (MPC) inhibitor, is advancing into a Phase 2 clinical trial
for the treatment of NASH. Poxel also has additional earlier-stage
programs targeting metabolic, specialty and rare diseases. The
Company intends to generate further growth through strategic
partnerships and pipeline development. Listed on Euronext Paris,
Poxel is headquartered in Lyon, France, and has subsidiaries in
Boston, MA, and Tokyo, Japan. For more information, please visit:
www.poxelpharma.com.
In the context of the COVID-19 outbreak, which was declared a
pandemic by the World Health Organization (WHO) on March 12, 2020,
the Company is regularly reviewing the impact of the outbreak on
its business.
As of the date of this press release, and based on publicly
available information, the Company has not identified the
occurrence of any material negative effect on its business due to
the COVID-19 pandemic that remains unresolved. However, the Company
anticipates that the COVID-19 pandemic could have further material
negative impact on its business operations. The worldwide impact of
COVID-19 may notably affect the Company’s internal organization and
efficiency, particularly in countries where it operates and where
confinement measures are implemented by the authorities. In
addition, COVID-19 may impact market conditions and the Company’s
ability to seek additional funding or enter into partnerships.
Particularly, delays in the supply of drug substance or drug
products, in the initiation or the timing of results of preclinical
and/or clinical trials, as well as delays linked to the
responsiveness of regulatory authorities could occur, which could
potentially have an impact on the Company’s development programs
and partnered programs. The Company will continue to actively
monitor the situation.
All statements other than statements of historical fact included
in this press release about future events are subject to (i) change
without notice and (ii) factors beyond the Company’s control. These
statements may include, without limitation, any statements preceded
by, followed by or including words such as “target,” “believe,”
“expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,”
“project,” “will,” “can have,” “likely,” “should,” “would,” “could”
and other words and terms of similar meaning or the negative
thereof. Forward-looking statements are subject to inherent risks
and uncertainties beyond the Company’s control that could cause the
Company’s actual results or performance to be materially different
from the expected results or performance expressed or implied by
such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200921005664/en/
Poxel SA Jonae R. Barnes Senior Vice President, Investor
Relations, Corporate Communications and Public Relations
jonae.barnes@poxelpharma.com +1 617 818 2985
Aurélie Bozza Investor Relations & Communication Director
aurelie.bozza@poxelpharma.com +33 6 99 81 08 36
Investor relations / Media - EU/US Trophic Communications
Joanne Tudorica or Valeria Fisher tudorica@trophic.eu or
fisher@trophic.eu +49 171 351 2733 or +49 175 804 1816
Investor relations / Media - France NewCap Emmanuel Huynh
or Arthur Rouillé poxel@newcap.eu +33 1 44 71 94 94
Poxel (EU:POXEL)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Poxel (EU:POXEL)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024